| FCγ chimeric receptor-engineered T cells: methodology, advantages, limitations, and clinical relevance S Caratelli, T Sconocchia, R Arriga, A Coppola, G Lanzilli, D Lauro, ... Frontiers in Immunology 8, 457, 2017 | 59 | 2017 |
| In vitro elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or … S Caratelli, R Arriga, T Sconocchia, A Ottaviani, G Lanzilli, D Pastore, ... International journal of cancer 146 (1), 236-247, 2020 | 36 | 2020 |
| Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: preclinical evidence versus clinical outcomes HE Marei, A Althani, T Caceci, R Arriga, T Sconocchia, A Ottaviani, ... Biochemical Pharmacology 166, 335-346, 2019 | 25 | 2019 |
| Regulation of the immune system in health and disease by members of the bone morphogenetic protein family T Sconocchia, G Sconocchia Frontiers in immunology 12, 802346, 2021 | 24 | 2021 |
| CD16‐158‐valine chimeric receptor T cells overcome the resistance of KRAS‐mutated colorectal carcinoma cells to cetuximab R Arriga, S Caratelli, G Lanzilli, A Ottaviani, C Cenciarelli, T Sconocchia, ... International journal of cancer 146 (9), 2531-2538, 2020 | 18 | 2020 |
| Bone morphogenetic protein signaling regulates skin inflammation via modulating dendritic cell function T Sconocchia, M Hochgerner, E Schwarzenberger, C Tam-Amersdorfer, ... Journal of Allergy and Clinical Immunology 147 (5), 1810-1822. e9, 2021 | 16 | 2021 |
| Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage R Arriga, S Caratelli, A Coppola, GC Spagnoli, A Venditti, S Amadori, ... Oncotarget 7 (2), 2070, 2016 | 16 | 2016 |
| BMP7 aberrantly induced in the psoriatic epidermis instructs inflammation-associated Langerhans cells I Borek, R Köffel, J Feichtinger, M Spies, E Glitzner-Zeis, M Hochgerner, ... Journal of allergy and clinical immunology 145 (4), 1194-1207. e11, 2020 | 14 | 2020 |
| Immunotherapy as a turning point in the treatment of acute myeloid leukemia A Aureli, B Marziani, T Sconocchia, MI Del Principe, E Buzzatti, ... Cancers 13 (24), 6246, 2021 | 12 | 2021 |
| Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond A Aureli, B Marziani, A Venditti, T Sconocchia, G Sconocchia Cancers 15 (13), 3346, 2023 | 9 | 2023 |
| Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities J Foßelteder, G Pabst, T Sconocchia, A Schlacher, L Auinger, K Kashofer, ... Leukemia 37 (4), 843-853, 2023 | 7 | 2023 |
| The miR-424 (322)/503 gene cluster regulates pro-versus anti-inflammatory skin DC subset differentiation by modulating TGF-β signaling V Zyulina, KK Yan, B Ju, E Schwarzenberger, C Passegger, ... Cell Reports 35 (4), 2021 | 6 | 2021 |
| Engineering oncogenic heterozygous gain-of-function mutations in human hematopoietic stem and progenitor cells T Sconocchia, J Foßelteder, T Köhnke, R Majeti, A Reinisch JoVE (Journal of Visualized Experiments), e64558, 2023 | 5 | 2023 |
| Immunomodulatory Effects of Aronia Juice Polyphenols—Results of a Randomized Placebo-Controlled Human Intervention Study and Cell Culture Experiments S Lackner, T Sconocchia, T Ziegler, C Passegger, N Meier-Allard, ... Antioxidants 11 (7), 1283, 2022 | 5 | 2022 |
| Langerhans cell histiocytosis: current advances in molecular pathogenesis T Sconocchia, J Foßelteder, G Sconocchia, A Reinisch Frontiers in Immunology 14, 1275085, 2023 | 4 | 2023 |
| Induction of the sphingosine‐1‐phosphate signaling pathway by TGF‐β1 during Langerhans‐type dendritic cell differentiation. T Sconocchia, I Del Gaudio, A Meshcheryakova, D Mechtcheriakova, ... European Journal of Immunology 51 (7), 2021 | 3 | 2021 |
| BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis T Sconocchia, J Foßelteder, L Auinger, E Özkaya, T Benezeder, M Lang, ... Leukemia 37 (11), 2292-2296, 2023 | 1 | 2023 |
| Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment G Sconocchia, G Lanzilli, V Cesarini, DA Silvestris, K Rezvani, R Arriga, ... Life science alliance 5 (12), 2022 | 1 | 2022 |
| EGFR+ Glioblastoma Stem Cells Targeting by CD16158V-Chimeric Receptor T Cells and Cetuximab C Cenciarelli, S Caratelli, R Arriga, G Lanzilli, A Ottaviani, T Sconocchia, ... J. Res 1, 24-35, 2021 | 1 | 2021 |
| Antibody-Independent Antitumor Effects of Cd32A-Chimeric Receptor T Cells: Implications for Breast Cancer Prognosis and Treatment G Sconocchia, G Lanzilli, V Cesarini, DA Silvestris, R Arriga, K Rezvani, ... bioRxiv, 2021.12. 22.473841, 2021 | | 2021 |
